# AI Research Acceleration Model v0.8

## Technical Report: Full Probabilistic Framework

**Version**: 0.8
**Date**: January 2026
**Previous Version**: v0.7

---

## Executive Summary

v0.8 introduces a complete probabilistic framework for the AI Research Acceleration Model:

1. **Monte Carlo Uncertainty Propagation**: Full posterior distributions, not just point estimates
2. **Prospective Validation Framework**: Registered predictions for future validation
3. **Scenario Analysis**: Explicit assumptions with probability weights
4. **Regulatory Evolution Modeling**: AI-era regulatory pathway scenarios

**Key Result**: v0.8 quantifies that drug discovery acceleration is bounded by clinical trials under all but the most transformative regulatory scenarios (90% CI: 1.1-1.8x for 2030).

---

## 1. Monte Carlo Uncertainty Propagation

### 1.1 Parameter Distributions

Each model parameter now has an associated probability distribution:

| Parameter | Domain | Distribution | Mean | Std |
|-----------|--------|--------------|------|-----|
| AI ceiling | Structural Bio | Lognormal | 1000x | 500 |
| Automation ceiling | All | Lognormal | 50x | 20 |
| Bypass potential | Structural Bio | Beta(10,2) | 0.80 | - |
| Clinical acceleration | Drug Discovery | Triangular | 1.1x | [1.0-1.5] |
| Synthesis automation | Materials | Lognormal | 3x | 1.5 |

### 1.2 Monte Carlo Procedure

```python
# 10,000 samples per forecast
for each sample:
    1. Draw parameter values from distributions
    2. Run model with sampled parameters
    3. Record acceleration output

# Compute statistics
mean, median, std = from samples
ci_50 = [25th, 75th percentile]
ci_90 = [5th, 95th percentile]
ci_95 = [2.5th, 97.5th percentile]
```

### 1.3 Results (2030)

| Domain | Mean | Median | 90% CI | Skewness |
|--------|------|--------|--------|----------|
| Structural Biology | 4.7x | 4.5x | [3.2-7.0] | 1.31 |
| Drug Discovery | 1.4x | 1.4x | [1.1-1.8] | 0.64 |
| Materials Science | 1.2x | 1.0x | [1.0-2.0] | 2.69 |
| Protein Design | 2.5x | 2.5x | [2.0-3.1] | 0.40 |
| Clinical Genomics | 2.0x | 2.0x | [1.7-2.2] | 0.04 |

---

## 2. Prospective Validation Framework

### 2.1 Prediction Registry

All v0.8 predictions are registered with:
- Unique prediction ID
- Model version
- Prediction date
- Data cutoff date
- Explicit assumptions
- Confidence intervals

### 2.2 Scoring Mechanism

When outcomes are observed:
- Absolute error
- Log error
- Within 90% CI? (binary)
- Within 50% CI? (binary)
- Brier score (probabilistic calibration)

### 2.3 Calibration Analysis

Ideally:
- 90% of outcomes within 90% CI
- 50% of outcomes within 50% CI

If < 85% within 90% CI: Model is **overconfident** → widen intervals
If > 95% within 90% CI: Model is **underconfident** → narrow intervals

---

## 3. Scenario Analysis

### 3.1 Scenario Definitions

| Scenario | Probability | Description |
|----------|-------------|-------------|
| Pessimistic | 10% | AI winter, regulatory backlash |
| Conservative | 20% | Slower progress, modest automation |
| Baseline | 40% | Expected trajectory |
| Optimistic | 20% | Faster AI, good automation, favorable regulation |
| Breakthrough | 10% | Transformative advances |

### 3.2 Explicit Assumptions

Each scenario has documented assumptions:

**Baseline Assumptions**:
- AI progress continues at 2020-2024 rates (P=80%)
- Lab automation scales (P=70%)
- Regulatory stability (P=60%)
- Data sharing improves (P=50%)

### 3.3 Ensemble Predictions

Probability-weighted combination of scenarios:

```
Ensemble = Σ (scenario_probability × scenario_acceleration)
```

---

## 4. Regulatory Evolution Modeling

### 4.1 Regulatory Scenarios (Drug Discovery)

| Scenario | Probability | Phase 3 Accel | End-to-End | Timeline |
|----------|-------------|---------------|------------|----------|
| Status Quo | 30% | 1.0x | 1.0x | Now |
| Incremental | 35% | 1.2x | 1.2x | 2027 |
| AI-Assisted | 20% | 1.5x | 1.4x | 2030 |
| AI-Primary | 10% | 2.5x | 2.0x | 2035 |
| Transformed | 5% | 8.0x | 5.0x | 2045 |

### 4.2 Key Insight

Even under AI-Primary pathways (10% probability by 2035), clinical trials still constrain drug discovery to ~2x acceleration. Only the "Transformed" scenario (5% probability) enables >3x acceleration.

---

## 5. Files Created

### Source Code (`src/`)
- `monte_carlo.py` - Monte Carlo simulation engine
- `prospective_validation.py` - Prediction registry and scoring
- `scenario_analysis.py` - Scenario framework with explicit assumptions
- `regulatory_scenarios.py` - Regulatory evolution modeling
- `integrated_v08_model.py` - Full probabilistic model

---

## 6. Usage

```python
from integrated_v08_model import IntegratedV08Model

# Create model with 10,000 Monte Carlo samples
model = IntegratedV08Model(
    domain="drug_discovery",
    n_samples=10000,
    seed=42
)

# Get probabilistic forecast
f = model.forecast(2030)

# Access full distribution
print(f"Mean: {f.mean_acceleration:.1f}x")
print(f"Median: {f.median_acceleration:.1f}x")
print(f"90% CI: [{f.ci_90[0]:.1f}x - {f.ci_90[1]:.1f}x]")
print(f"Skewness: {f.skewness:.2f}")

# Access scenario breakdown
for scenario, accel in f.scenario_forecasts.items():
    prob = f.scenario_probabilities[scenario]
    print(f"{scenario.value}: {accel:.1f}x (P={prob:.0%})")
```

---

## 7. Conclusion

v0.8 transforms the AI Research Acceleration Model from a point-estimate tool to a full probabilistic framework. Key improvements:

1. **Uncertainty quantification**: Every prediction includes confidence intervals
2. **Prospective validation**: Predictions registered for future scoring
3. **Explicit assumptions**: Scenario probabilities documented
4. **Regulatory modeling**: Drug discovery bounded by clinical trials

The model is now suitable for policy decisions requiring rigorous uncertainty analysis.

---

*v0.8 Technical Report completed January 14, 2026*
